Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 5
1938 5
1939 2
1940 3
1941 2
1942 2
1943 4
1944 1
1945 29
1946 59
1947 84
1948 109
1949 95
1950 288
1951 225
1952 166
1953 148
1954 132
1955 132
1956 168
1957 185
1958 177
1959 210
1960 236
1961 276
1962 307
1963 552
1964 735
1965 622
1966 590
1967 735
1968 888
1969 1008
1970 1005
1971 1060
1972 1246
1973 1416
1974 1657
1975 1851
1976 1713
1977 1849
1978 1821
1979 1990
1980 2057
1981 2086
1982 2051
1983 2180
1984 2243
1985 2222
1986 2312
1987 2366
1988 2264
1989 2376
1990 2425
1991 2355
1992 2363
1993 2350
1994 2156
1995 2359
1996 2283
1997 2387
1998 2413
1999 2591
2000 2877
2001 3011
2002 3131
2003 3212
2004 3216
2005 3480
2006 3600
2007 3546
2008 3755
2009 3559
2010 3600
2011 3600
2012 3643
2013 3559
2014 3573
2015 3472
2016 3364
2017 3273
2018 3301
2019 3196
2020 3361
2021 3387
2022 3105
2023 2886
2024 1042

Text availability

Article attribute

Article type

Publication date

Search Results

141,197 results

Results by year

Filters applied: . Clear all
Page 1
Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17beta-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.
Duijkers I, Klipping C, Heger-Mahn D, Fayad GN, Frenkl TL, Cruz SM, Korver T. Duijkers I, et al. Eur J Contracept Reprod Health Care. 2018 Aug;23(4):245-254. doi: 10.1080/13625187.2018.1506101. Epub 2018 Sep 11. Eur J Contracept Reprod Health Care. 2018. PMID: 30203681 Clinical Trial.
PURPOSE: To identify at least one contraceptive vaginal ring that effectively inhibits ovulation and demonstrates cycle control that is non-inferior to NuvaRing() (Merck Sharp & Dohme B.V., The Netherlands) in terms of an unscheduled bleeding incidence, with a non-infe …
PURPOSE: To identify at least one contraceptive vaginal ring that effectively inhibits ovulation and demonstrates cycle control that is non- …
Pharmacokinetic bioequivalence, safety and acceptability of Ornibel(), a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring() (etonogestrel/ethinylestradiol 11.7/2.7 mg).
Algorta J, Diaz M, de Benito R, Lefebvre M, Sicard E, Furtado M, Regidor PA, Ronchi C. Algorta J, et al. Eur J Contracept Reprod Health Care. 2017 Dec;22(6):429-438. doi: 10.1080/13625187.2017.1413179. Epub 2018 Jan 16. Eur J Contracept Reprod Health Care. 2017. PMID: 29336615 Clinical Trial.
All subjects received both treatments for 28 days in each of two periods, separated by a 28 days washout. Ornibel() contains etonogestrel/ethinylestradiol 11.00/3.47 mg and Nuvaring() contains etonogestrel/ethinylestradiol 11.7/2.7 mg, both ring …
All subjects received both treatments for 28 days in each of two periods, separated by a 28 days washout. Ornibel() contains etonogestrel …
Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
Dogterom P, van den Heuvel MW, Thomsen T. Dogterom P, et al. Clin Pharmacokinet. 2005;44(4):429-38. doi: 10.2165/00003088-200544040-00007. Clin Pharmacokinet. 2005. PMID: 15828855 Clinical Trial.
BACKGROUND: Two pharmacokinetic studies were performed to investigate whether there is any interaction between etonogestrel or ethinylestradiol released from the combined contraceptive vaginal ring NuvaRing and concomitant treatment with orally administered a …
BACKGROUND: Two pharmacokinetic studies were performed to investigate whether there is any interaction between etonogestrel or eth …
Complete and robust ovulation inhibition with NuvaRing.
Killick S. Killick S. Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:13-8; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659397 Review.
NuvaRing, a novel contraceptive vaginal ring, releases 15 microgram of ethinylestradiol (EE) and 120 microgram etonogestrel (ENG) per day. ...The use of NuvaRing for the recommended 3-week period completely inhibited ovulation. ...
NuvaRing, a novel contraceptive vaginal ring, releases 15 microgram of ethinylestradiol (EE) and 120 microgram etonogestrel …
Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing.
Roumen F. Roumen F. Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:19-24; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659398 Review.
NuvaRing is a novel combined contraceptive vaginal ring that releases 15 microg of ethinylestradiol and 120 microgram etonogestrel per day. Each ring is used for one cycle, comprising 3 weeks continuous use of the ring followed by a 1-week ring-free period. T …
NuvaRing is a novel combined contraceptive vaginal ring that releases 15 microg of ethinylestradiol and 120 microgram etono …
The contraceptive vaginal ring.
Edwardson J, Jamshidi R. Edwardson J, et al. Semin Reprod Med. 2010 Mar;28(2):133-9. doi: 10.1055/s-0030-1248138. Epub 2010 Mar 29. Semin Reprod Med. 2010. PMID: 20352563 Review.
The contraceptive vaginal ring offers effective contraception that is self-administered, requires less frequent dosing than many other forms of contraception, and provides low doses of hormones. NuvaRing (Organon, Oss, The Netherlands), the only contraceptive vaginal ring …
The contraceptive vaginal ring offers effective contraception that is self-administered, requires less frequent dosing than many other forms …
The combined contraceptive vaginal device (NuvaRing): a comprehensive review.
Sarkar NN. Sarkar NN. Eur J Contracept Reprod Health Care. 2005 Jun;10(2):73-8. doi: 10.1080/13625180500131683. Eur J Contracept Reprod Health Care. 2005. PMID: 16147810 Review.
METHODS: The data were extracted from the literature using computerised MEDLINE system. NuvaRing is a new combined hormonal contraceptive vaginal ring made of ethylene-vinyl-acetate copolymer, releasing 120 microg etonorgestrel and 15 microg ethinyloestradiol per da …
METHODS: The data were extracted from the literature using computerised MEDLINE system. NuvaRing is a new combined hormonal contracep …
High acceptability and satisfaction with NuvaRing use.
Szarewski A. Szarewski A. Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:31-6; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659400 Review.
NuvaRing is a combined contraceptive vaginal ring that releases constant low doses of ethinylestradiol and etonogestrel. ...In conclusion, this analysis shows that users express good acceptability and a high level of satisfaction with NuvaRing....
NuvaRing is a combined contraceptive vaginal ring that releases constant low doses of ethinylestradiol and etonogestrel …
The contraceptive vaginal ring, NuvaRing(), a decade after its introduction.
Roumen FJ, Mishell DR Jr. Roumen FJ, et al. Eur J Contracept Reprod Health Care. 2012 Dec;17(6):415-27. doi: 10.3109/13625187.2012.713535. Epub 2012 Oct 31. Eur J Contracept Reprod Health Care. 2012. PMID: 23113828 Review.
OBJECTIVES: To review the clinical experience with the contraceptive vaginal ring (CVR, NuvaRing()) since its introduction over ten years ago. METHODS: The literature was searched on efficacy, cycle control, safety, user preference and satisfaction of the CVR in comparison …
OBJECTIVES: To review the clinical experience with the contraceptive vaginal ring (CVR, NuvaRing()) since its introduction over ten y …
A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon.
Weisberg E, Croxatto HB, Findlay JK, Burger HG, Fraser IS. Weisberg E, et al. Contraception. 2011 Dec;84(6):600-8. doi: 10.1016/j.contraception.2011.04.008. Epub 2011 Jun 8. Contraception. 2011. PMID: 22078189 Clinical Trial.
BACKGROUND: Mifepristone alone or in combination with ethinyl estradiol (EE) can effectively stop an episode of uterine bleeding in women using the etonogestrel-releasing contraceptive implant, Implanon but could impair contraceptive efficacy. ...The increase …
BACKGROUND: Mifepristone alone or in combination with ethinyl estradiol (EE) can effectively stop an episode of uterine bleedi …
141,197 results
You have reached the last available page of results. Please see the User Guide for more information.